Investment analysts at Roth Capital initiated coverage on shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in a research report issued on Tuesday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Other equities research analysts have also issued research reports about the company. Maxim Group set a $5.00 price objective on Viking Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 10th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Viking Therapeutics in a research note on Friday, November 10th. Finally, ValuEngine raised Viking Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th.

Shares of Viking Therapeutics (NASDAQ VKTX) traded down $0.02 during midday trading on Tuesday, reaching $2.77. The company’s stock had a trading volume of 172,100 shares, compared to its average volume of 311,324. Viking Therapeutics has a 12-month low of $0.88 and a 12-month high of $3.24.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). equities research analysts forecast that Viking Therapeutics will post -0.86 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Viking Therapeutics, Inc. (VKTX) Research Coverage Started at Roth Capital” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/21/viking-therapeutics-inc-vktx-research-coverage-started-at-roth-capital.html.

A number of large investors have recently added to or reduced their stakes in VKTX. Sio Capital Management LLC lifted its holdings in Viking Therapeutics by 53.3% during the 3rd quarter. Sio Capital Management LLC now owns 849,905 shares of the biotechnology company’s stock worth $1,191,000 after buying an additional 295,523 shares during the last quarter. GRT Capital Partners L.L.C. lifted its holdings in Viking Therapeutics by 187.8% during the 4th quarter. GRT Capital Partners L.L.C. now owns 94,978 shares of the biotechnology company’s stock worth $113,000 after buying an additional 61,978 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Viking Therapeutics by 666.2% during the 4th quarter. Renaissance Technologies LLC now owns 163,200 shares of the biotechnology company’s stock worth $194,000 after buying an additional 141,900 shares during the last quarter. Virtu KCG Holdings LLC bought a new position in Viking Therapeutics during the 2nd quarter worth approximately $124,000. Finally, Sabby Management LLC bought a new position in Viking Therapeutics during the 2nd quarter worth approximately $525,000. 8.84% of the stock is currently owned by institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.